Combination therapy for the treatment of cancer
AssigneeNovartis AG
InventorsYan CHEN, Xizhong HUANG, Sunkyu KIM
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to a pharmaceutical combination comprising (1) a first agent which is a CDK inhibitor or a pharmaceutically acceptable salt thereof and (2) a second agent which is an anti-hormonal agent or a pharmaceutically acceptable salt thereof. The present disclosure also relates to a pharmaceutical combination comprising (1) a first agent which is a CDK inhibitor or a pharmaceutically acceptable salt thereof, (2) a second agent which is an anti-hormonal agent or a pharmaceutically acceptable salt thereof, and (3) a third agent which is an agent that regulates the PI3K/Akt/mTOR pathway or a pharmaceutically acceptable salt thereof.
Claims5
1-42. (canceled)
A method of treating HR+ breast cancer in a human in need of therapy for the breast cancer, comprising administering to the human a jointly therapeutically effective amount of (1) Compound A1, or a pharmaceutically acceptable salt thereof:
- and (2) fulvestrant, wherein the administration provides to the human a dose of 200 mg/day, 400 mg/day or 600 mg/day of Compound A1.
Dependencies are inferred from the claim text.